BioSpace News Archive

Deals

Axonics® Announces Pricing of Public Offering of Common Stock - Nov. 20, 2019

Axonics Modulation Technologies, Inc. announced the pricing of its public offering of 5,000,000 shares of its common stock at a public offering price of $22.00 per share, before underwriting discounts and commissions.

November 19, 2019
·
4 min read
Drug Development

CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib

CStone Pharmaceuticals announced that the first patient has been dosed in the Phase I bridging registrational study of ivosidenib in China.

November 19, 2019
·
9 min read
Abzena Showcases Discovery and Developability Services at PEGS Europe 2019

Bespoke approach generates high affinity antibodies and selects lead candidates with the strongest chances of success in the clinic

November 19, 2019
·
2 min read
Business

Castor Establishes Advisory Board of Industry Leaders to Maximize the Impact of its Clinical Data Platform

Industry veterans including Craig Lipset will support the Castor’s vision to advance the future of clinical research

November 19, 2019
·
8 min read
PharmaMar has presented results of its antitumor compounds trabectedin and plocabulin at the CTOS Congress

PharmaMar had a notable presence at CTOS with two oral presentations and six posters on trabectedin and two posters on plocabulin.

November 19, 2019
·
6 min read
Policy

Martin Shkreli Will Continue to Serve Prison Sentence After Supreme Court Denies Appeal

On Monday, the U.S. Supreme Court refused to overturn his seven-year conviction for securities fraud.

November 19, 2019
·
2 min read
·
Alex Keown
Drug Development

CRISPR Therapeutics and Vertex: Promising Gene Therapy Data for Sickle Cell Disease and Beta Thalassemia

CRISPR Therapeutics and Vertex Pharmaceuticals announced positive interim data from the first two patients in the companies’ ongoing Phase I/II clinical trials of its CRISPR/Cas9 gene-editing therapy CTX001.

November 19, 2019
·
3 min read
·
Mark Terry
Drug Development

Myovant’s Prostate Cancer Drug Ready to Submit to FDA Following Positive Trial Results

Myovant announced that its Phase III HERO trial relugolix met its primary endpoint and six key secondary endpoints in advanced prostate cancer.

November 19, 2019
·
2 min read
·
Mark Terry
Preclinical Research Shows Promise For New Approach to Treating Progeria

New research is shedding light on a possible new approach to treating the rare and fatal premature aging syndrome, progeria.

November 19, 2019
·
2 min read
·
Alex Keown
Business

Up-and-Coming Female Powerhouses of Biotech

Balancing slim chances with a drive for success, each of these women beat the biotech odds.

November 19, 2019
·
3 min read
·
Elizabeth Glasure